Long-acting EVO301 Shows Promise in Proof-of-concept AD Study

Evommune, Inc.’s EVO301 performed well in a Phase 2a proof-of-concept study in atopic dermatitis (AD), finds research presented at the 2026 European Academy of Dermatology and Venereology Congress in Vienna, Austria.